ASSESSMENT OF THE STATE OF CELLULAR AND HUMORAL IMMUNITY OF A PERSON UNDER THE INFLUENCE OF THE DRUG ESBERITOX AGAINST THE BACKGROUND OF VACCINATION FROM SARS-COV-2

  • A. Kurchenko MD, Professor, Head of the Department of Clinical Immunology and Allergology with a section of Medical Genetics, O.O. Bogomolets National Medical University
  • G. Fedoruk MD, candidate of Medical Sciences, Associate Professor of the Department of Clinical Immunology and Allergology with a section of Medical Genetics, O.O. Bogomolets National Medical University
  • V. Savchenko Ph.D., senior researcher lab. of Immunology, SI «Institute of Urology named after Academician O.F. Vozianov NAMS of Ukraine»
Keywords: vaccination against COVID-19, antibodies, B cells, NK cells, CD314, CD94, immunoadaptive effect.

Abstract

The aim of the study – to study the effect of Esberitox on humoral (by the level of total antibodies and quantitative detection of IgG to the Spike antigen of the SARS-CoV-2) and cellular (by determining the phenotypes of lymphocyte populations CD3, CD4, CD8, CD56, CD19, CD45 with an assessment expression of activating CD314 (NKG2D) and inhibitory CD94 (NKG2A) receptors on NK cells and lymphocytes) links of the immune system before vaccination and after receiving the first dose of the vaccine.

Materials and methods. The study involved 30 clinically healthy volunteers (with informed consent for examination and administration of the drug), who had not been ill with Covid-19 during the previous 3 months before entering the study project, who took Esberitox, and selected according to the relevant criteria for the control group – 20 clinically healthy people. The studies were carried out three times: three days before vaccination – before starting Esberitox, immediately before vaccination, and before the second vaccination – 21 days after receiving the first dose of the vaccine.

Results. The use of the drug Esberitox according to the selected scheme stimulates the production of specific antibodies to Covid-19 – in the case of normalization of the number of B cells. The drug is an immunomodulator that affects the regulatory activating CD314 (NKG2D) and inhibitory CD94 (NKG2A) receptors.

Conclusions. The study showed that the drug Esberitox, prescribed as an immunomodulator, during the vaccination process stimulates the production of specific antibodies to COVID-19, if the number of B cells is normalized. The drug Esberitox is capable of influencing the regulatory activating and inhibitory receptors of NK and T cells, which play an important role in nonspecific cellular defense against the SARS-CoV-2 coronavirus and can be used in the schemes of immunorehabilitation of postcovid syndrome in immunocompromised patients.

References

Bostelmann HC, Bödeker RH, Dames W, Henneicke-von Zepelin HH, Siegers CP, Stammwitz U. Immunmodulation durch pflanzliche Wirkstoffe. Doppelblindstudie an einer medizinischen Universitätsklinik am Adjuvansmodell zur Hepatitis-B-Impfung [Immunomodulation by herbal agents. A doubleblind study in a medical university hospital involving a hepatitis B vaccine adjuvant model]. Fortschr Med Orig. 2002 Dec 5;120(4):119-23. German. PMID: 12613268.

В.Г. Майданник, Е.А. Емчинская, Иммуномодулирующие эффекты растительного препарата ЭСБЕРИТОКС у детей с острыми респираторными инфекциями. Міжнародний журнал педіатрії, акушерства та гінекології Січень/Березень 2017 Том 11 №1. УДК 616.22/231 – 002 – 007.271 – 053.2

Andrea Sáez-Borderías, Neus Romo, Giuliana Magri, Mónica Gumá, Ana Angulo and Miguel López-Botet. IL-12-Dependent Inducible Expression of the CD94/NKG2A Inhibitory Receptor Regulates CD94/NKG2C+ NK Cell Function. J Immunol January 15, 2009, 182 (2) 829-836; DOI: https://doi.org/10.4049/jimmunol.182.2.829

Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-74. doi: 10.1146/annurev.immunol.23.021704.115526. PMID: 15771571.

Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004 Jan 28;23(2):255-9. doi: 10.1038/sj.emboj.7600019. Epub 2003 Dec 18. PMID: 14685277; PMCID: PMC1271745.

van Eeden C, Khan L, Osman MS, Cohen Tervaert JW. Natural Killer Cell Dysfunction and Its Role in COVID-19. Int J Mol Sci. 2020 Sep 1;21(17):6351. doi: 10.3390/ijms21176351. PMID: 32883007; PMCID: PMC7503862.

Bortolotti D, Gentili V, Rizzo S, Rotola A, Rizzo R. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway. Cells. 2020 Aug 26;9(9):1975. doi: 10.3390/cells9091975. PMID: 32859121; PMCID: PMC7563485.

Market M, Angka L, Martel AB, Bastin D, Olanubi O, Tennakoon G, Boucher DM, Ng J, Ardolino M, Auer RC. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. Front Immunol. 2020 Jun 23;11:1512. doi: 10.3389/fimmu.2020.01512. PMID: 32655581; PMCID: PMC7324763.

Mitsuyama Y, Yamakawa K, Kayano K, Maruyama M, Wada T, Fujimi S. Prolonged enhancement of cytotoxic T lymphocytes in the post-recovery state of severe COVID-19. J Intensive Care. 2021 Dec 20;9(1):76. doi: 10.1186/s40560-021-00591-3. PMID: 34930468; PMCID: PMC8685802.

Boozari M, Hosseinzadeh H. Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies. Phytother Res. 2021 Feb;35(2):864-876. doi: 10.1002/ptr.6873.Epub 2020 Sep 27. PMID: 32985017.

Keflie TS, Biesalski HK. Micronutrients and bioactive substances: Their potential roles in combating COVID-19. Nutrition.2021 Apr;84:111103. doi: 10.1016/j.nut.2020.111103. Epub 2020 Dec 4. PMID: 33450678; PMCID: PMC7717879.

Aucoin M, Cooley K, Saunders PR, Car J, Anheyer D, Medina DN, Cardozo V, Remy D, Hannan N, Garber A. The effect of Echinacea spp. on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review. Adv Integr Med. 2020 Dec;7(4):203-217. doi: 10.1016/j.aimed.2020.07.004. Epub 2020 Aug 1. PMID: 32837894; PMCID: PMC7395221.

Aucoin M, Cardozo V, McLaren MD, Garber A, Remy D, Baker J, Gratton A, Kala MA, Monteiro S, Warder C, Perciballi A, Cooley K. A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19? Metabol Open. 2021 Sep;11:100115. doi: 10.1016/j.metop.2021.100115. Epub 2021 Jul 29. PMID: 34341776; PMCID: PMC8320399.

Silveira D, Prieto-Garcia JM, Boylan F, Estrada O, Fonseca-Bazzo YM, Jamal CM, Magalhães PO, Pereira EO, Tomczyk M, Heinrich M. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? Front Pharmacol. 2020 Sep 23;11:581840. doi: 10.3389/fphar.2020.581840. PMID: 33071794; PMCID: PMC7542597.

Brendler T, Al-Harrasi A, Bauer R, Gafner S, Hardy ML, Heinrich M, Hosseinzadeh H, Izzo AA, Michaelis M, Nassiri-Asl M, Panossian A, Wasser SP, Williamson EM. Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice. Phytother Res. 2021 Jun;35(6):3013-3031. doi: 10.1002/ptr.7008. Epub 2020 Dec 29. PMID: 33373071.

Wilk, A.J., Rustagi, A., Zhao, N.Q. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med 26, 1070–1076 (2020). https://doi.org/10.1038/s41591-020-0944-y

Signer J, Jonsdottir HR, Albrich WC, Strasser M, Züst R, Ryter S, Ackermann-Gäumann R, Lenz N, Siegrist D, Suter A, Schoop R, Engler OB. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol J. 2020 Sep 9;17(1):136. doi: 10.1186/s12985-020-01401- 2. Erratum in: Virol J. 2020 Nov 9;17(1):172. PMID: 32907596; PMCID: PMC7479405.

Percival SS. Use of echinacea in medicine. Biochem Pharmacol. 2000 Jul 15;60(2):155-8. doi: 10.1016/s0006-2952(99)00413-x. PMID: 10825459.

Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2005 Aug;57(8):929-54. doi: 10.1211/0022357056127. PMID: 16102249.

Ghaemi A, Soleimanjahi H, Gill P, Arefian E, Soudi S, Hassan Z. Echinacea purpurea polysaccharide reduces the latency rate in herpes simplex virus type-1 infections. Intervirology. 2009;52(1):29-34. doi: 10.1159/000212988. Epub 2009 Apr 17. PMID: 19372701.

Barrett B, Brown R, Rakel D, Mundt M, Bone K, Barlow S, Ewers T. Echinacea for treating the common cold: a randomized trial. Ann Intern Med. 2010 Dec 21;153(12):769-77 doi: 10.7326/0003-4819-153-12-201012210-00003. PMID: 21173411; PMCID: PMC3056276.

Upton, R., Graff, A., Swisher, D., McGuffin, M., Pizzorno, J., & Prill, R. (2004). Echinacea pupurea Root: Echinacea purpurea (L.) Moench. Standards of Analysis, Quality Control, and Therapeutics. American Herbal Pharmacopoeia and Therapeutic Compendium, 1-53.

Nagoor Meeran MF, Javed H, Sharma C, Goyal SN, Kumar S, Jha NK, Ojha S. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. Heliyon. 2021 Feb;7(2):e05990. doi: 10.1016/j.heliyon. 2021.e05990. Epub 2021 Feb 8. PMID: 33585706; PMCID: PMC7870107.

Frost R, Bhamra SK, Pendry B, Heinrich M. COVID-19 and herbal practice: A United Kingdom practitioner survey. Adv Integr Med. 2021 Dec;8(4):256-260. doi: 10.1016/j. aimed.2021.09.003. Epub 2021 Sep 21. PMID: 34888138; PMCID: PMC8452456.

Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol. 2001 May;2(5):443-51. doi: 10.1038/87757. PMID: 11323699.

Xu Qiu-Yan, Xue Jian-Hang, Xiao Yao, Jia Zhi-Juan, Wu Meng-Juan, Liu Yan-Yun, Li Wei-Li, Liang Xian-Ming, Yang Tian-Ci. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days. Frontiers in Immunology, 2021, vol.12. DOI:10.3389/fimmu.2021.786554.

Kenji Maeda, MasayukiAmano, Yukari Uemura, KiyotoTsuchiya, Tomoko Matsushima, Kenta Noda, Yosuke Shimizu, Asuka Fujiwara, Yuki Takamatsu, Yasuko Ichikawa, Hidehiro Nishimura, Mari Kinoshita, Shota Matsumoto, Hiroyuki Gatanaga, Kazuhisa Yoshimura, Shin-ichi Oka, Ayako Mikami, Wataru Sugiura, Toshiyuki Sato, Tomokazu Yoshida, Shinya Shimada & Hiroaki Mitsuya. Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. Scientific Reports volume 11, Article number: 22848 (2021). doi:10.1038/s41598-021-01930-y https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000850-24/ES

Published
2022-05-31
How to Cite
Kurchenko, A., Fedoruk, G., & Savchenko, V. (2022). ASSESSMENT OF THE STATE OF CELLULAR AND HUMORAL IMMUNITY OF A PERSON UNDER THE INFLUENCE OF THE DRUG ESBERITOX AGAINST THE BACKGROUND OF VACCINATION FROM SARS-COV-2. Immunology and Allergy: Science and Practice, (4), 23-33. https://doi.org/10.37321/immunology.2021.4-02